TABLE III.
Summary of Clinical Characteristics, Drug Resistance Resistance, and the Virological and Biological Features of Patients With Both HBsAg and HBsAb (Group III)
| Patient no. | Gender/age | HBsAg (COI) | HBsAb (IU/L) | HBV DNA (log IU/ml) | HBeAg/HBeAb | ALT (IU/L) | HBV treatment | Drug resistant mutation |
|---|---|---|---|---|---|---|---|---|
| 1 | M/76 | 5509 | 196.4 | 3.47 | +−/+− | 13.4 | None | L180LMV, M204FILMV |
| 2 | M/63 | 5139 | 273.8 | 6.55 | +/− | 38.5 | None | A181APST |
| 3 | F/58 | 7715 | 23.02 | 7.52 | +/− | 262.1 | None | None |
| 4 | M/36 | 3430 | 13.97 | 5.23 | +/− | 74.2 | ADV | None |
| 5 | M/48 | 1114 | 19.08 | 4.91 | −/+ | 821.6 | IFN + LAM + ETV | None |
| 6 | M/25 | 1481 | 35.38 | 7.56 | +/− | 75.9 | None | None |
| 7 | M/35 | 6095 | 64.59 | 2.72 | −/+ | 47 | ADV | M204IM |
| 8 | M/54 | 633.7 | 127.2 | 3.32 | +/− | 117.8 | LAM + ADV | L180LMV, V173LMV, M204I |
| 9 | M/78 | 4136 | 99.33 | 3.77 | +/− | 27.2 | LAM | L180M, M204V |
| 10 | M/43 | 3447 | 30.91 | 2.94 | +/− | 35.5 | ADV + ETV + LdT | M204IM, A181APST |
| 11 | M/48 | 4634 | 262.5 | 2.70 | +/− | 19.2 | None | L180LMV, M204FILMV |
| 12 | M/52 | 6192 | 100.2 | 7.41 | −/+ | 266.2 | LAM | L180M, M204I |
| 13 | M/53 | 3295 | 50.74 | 2.70 | −/− | 21.5 | IFN + LAM + ADV | None |
| 14 | M/50 | 23.88 | 12.94 | 3.13 | +/− | 74.6 | LAM | None |
| 15a | M/31 | 5698 | 14.35 | 4.34 | +/− | 64.6 | LAM + ETV | A181V |
| 16a | M/16 | 5476 | 43.27 | 4.13 | +/− | 31.8 | None | M204IM, L180LMV |
| 17 | F/59 | 7038 | 38.64 | 5.11 | +/− | 306.1 | ADV | None |
M, male; F, female; ALT, alanine aminotransferase; ADV, adefovir dipivoxil; IFN, peginterferon; LAM, lamivudine; ETV, entecavir; LdT, telbivudine.
a
Patients who had received HBV vaccine.